CoChat
Sign Up
Cited by 1,068Pharmacogenetics and Drug MetabolismParkinson's Disease Mechanisms and TreatmentsNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 356 of the 356 references it cites were found in a registry or an index.

Catechol-O-methyltransferase (COMT): Biochemistry, Molecular Biology, Pharmacology, and Clinical Efficacy of the New Selective COMT Inhibitors

Männistö, Pekka T., Kaakkola, Seppo·1999·Pharmacological Reviews
DOI 10.1016/s0031-6997(24)01423-6
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1016/s0031-6997(24)01423-6

Cites

356 of 356 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Items 201–356 of 356

Research works printed but not linked: 13

  1. Davis, 1997, Effects of tolcapone withdrawal after 6 week treatment in Parkinsonian patients who exhibit end-of-dose wearing off (Abstract), Mov Disord, 12, 97
  2. European Medicine Evaluation Agency Press release: Recommendation for the suspension of the marketing authorization for Tasmar (tolcapone), London, 1998.
  3. Gordin, 1998, Pharmacokinetics of entacapone and catechol-O-methyltransferase (COMT) inhibition after frequent multiple dosing of entacapone and effect on levodopa metabolism, Eur J Neurol, 5, S165
  4. Gordin, 1998, Pharmacokinetics of the COMT inhibitor entacapone in liver failure and the effect of entacapone on liver function (Abstract), Neurology, 50, 387
  5. Grossman, 1992, Identification of the possible basis for inherited differences in human catechol-O-methyltransferase (Abstract), Trans Neurosci Soc, 18, 70
  6. Heikkinen H, Pentikäinen PJ, Saraheimo M, Ahtila S, Ottoila P Pharmacokinetics of entacapone, a new COMT-inhibitor, in man: A study using stable isotope technique (Abstract). 11th International Symposium on Parkinson’s Disease; March 26–30, Rome. 301 p, 1994.
  7. Jorga, 1997, Why should tolcapone be given at a lower dose to patients with liver cirrhosis?, Clin Pharmacol Ther, 61, 183
  8. Myllylä, 1997, Effect of entacapone as an adjunct to Sinemet and Madopar on the pharmacokinetics of levodopa in parkinsonian patients (Abstract), Mov Disord, 12, 103
  9. Oechsner, 1998, Elevated serum levels of dihydroxyphenylacetic acid (DOPAC) and dopamine after catechol-O-methyltransferase (COMT) inhibition (Abstract), Eur J Neurol, 5, 169
  10. Pentikäinen, 1990, Fate of nitecapone, a new catechol-O-methyltransferase inhibitor in man: A study with double isotope technique (Abstract), Clin Pharmacol Ther, 47, 156
  11. Pentikäinen, 1989, Human pharmacokinetics of OR-462, a new catechol-O-methyltransferase inhibitor (Abstract), Eur J Clin Pharmacol, 36, 110
  12. Riley, 1996, No evidence for linkage of chromosome 22 markers to schizophrenia in Southern African Bantu-speaking families, Am J Med Gen (Neuropsychiat Gen), 67, 515, 10.1002/(SICI)1096-8628(19961122)67:6<515::AID-AJMG2>3.0.CO;2-G · DOI
  13. Welsh, 1995, Improving quality of life in Parkinson’s disease: An experimental study of tolcapone (Abstract), Qual Life Res, 4, 503

Cited by

Sorted by citations

See all 1,068

Related

See all

Metadata

Authors
Männistö, P. T., & Kaakkola, S.
Affiliations
University of Eastern Finland (FI)
ORCID
Männistö, Pekka T.
Venue
Pharmacological Reviews
Publisher
Elsevier BV
Published
1999-12
Volume
51
Issue
4
Pages
593-628
ISSN
0031-6997 (ISSN-L)
DOI
10.1016/s0031-6997(24)01423-6
OpenAlex
W2131721815
Cited by
1,068
References
356
Citations by year
2026: 18 · 2025: 19 · 2024: 14 · 2023: 19 · 2022: 19 · 2021: 35 · 2020: 42 · 2019: 41 · 2018: 38 · 2017: 56 · 2016: 52 · 2015: 48 · 2014: 58 · 2013: 68 · 2012: 58
FWCI
15.59
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Pharmacological Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
catechol-O-methyltransferase, COMT inhibitors, enzyme kinetics, clinical efficacy
MeSH terms
Animals, Catechol O-Methyltransferase, Clinical Trials as Topic, Enzyme Inhibitors, Humans, Catechol O-Methyltransferase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review